Atif Iqbal

Also affiliated with Shifa International Hospital

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 8 papers. Top paper: “NCI Rectal-Anal Task Force consensus recommendations for design of clinical trials in rectal cancer”.

NCI Rectal-Anal Task Force consensus recommendations for design of clinical trials in rectal cancer

JNCI Journal of the National Cancer Institute(2023)10.1093/jnci/djad143

N/A

0.165DataRank · unranked

2 citations

Rebecca C. Auer, May Cho, N.A. Dasari, Cynthia Davies-Venn, Cathy Eng +36 more

Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.tps4121

N/A

0DataRank · unranked

4 citations

Greg Yothers, Scott Kopetz, Samuel A. Jacobs, Peter C. Lucas, Atif Iqbal +7 more

Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer:NRG-GI005 (COBRA).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.3_suppl.tps148

N/A

0DataRank · unranked

5 citations

Greg Yothers, Scott Kopetz, Samuel A. Jacobs, Peter C. Lucas, Atif Iqbal +7 more

Phase II/III study of Circulating tumOr DNA as a predictive BiomaRker in Adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.tps3622

N/A

0DataRank · unranked

2 citations

Greg Yothers, Scott Kopetz, Samuel A. Jacobs, Peter C. Lucas, Atif Iqbal +7 more

Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.4_suppl.tps233

N/A

0DataRank · unranked

3 citations

Greg Yothers, Scott Kopetz, Samuel A. Jacobs, Peter C. Lucas, Atif Iqbal +8 more

Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.4_suppl.tps259

N/A

0DataRank · unranked

1 citations

Greg Yothers, Scott Kopetz, Samuel A. Jacobs, Peter C. Lucas, Atif Iqbal +8 more

NRG-GI005 (COBRA): Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.4_suppl.tps261

N/A

0DataRank · unranked

17 citations

Greg Yothers, Scott Kopetz, Samuel A. Jacobs, Peter C. Lucas, Atif Iqbal +7 more

Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.tps3625

N/A

0DataRank · unranked

0 citations

Greg Yothers, Scott Kopetz, Shannon L. Puhalla, Peter C. Lucas, Atif Iqbal +8 more